A rare case of young multiple myeloma
DOI:
https://doi.org/10.18203/2349-3933.ijam20223404Keywords:
Multiple myeloma, Young, Plasma cellsAbstract
Multiple myeloma arises from a clonal population of plasma cells. It accounts for approximately 10% of all hematologic malignancies. It is a disease of the elderly and extremely rare in those under 50 years of age. Multiple myeloma is a malignancy of immune cells. The immune cells involved in tumorigenesis are especially plasma cells. The presentation may vary drastically in patients with this disease. The disease presentation ranges from an asymptomatic variant called Monoclonal gammopathy of unknown significance to a severe form of full-fledged multiple myeloma with systemic manifestations. The disease usually affects people aged more than 50. Here, we report a 40-year-old male who presented with anemia, and on further workup, he was diagnosed with multiple myeloma.
References
Albagoush SA, Shumway C, Azevedo AM. Multiple Myeloma. In: StatPearls. Treasure Island (FL): StatPearls Publishing. 2022.
Bora K. Distribution of multiple myeloma in India: Heterogeneity in incidence across age, sex, and geography. Cancer Epidemiol. 2019;59:215-20.
Avilés A, Zepeda G, Guzmán R, Talavera A, García EL, Díaz-Maqueo JC. Importancia pronóstica de la beta 2-microglobulina en mieloma múltiple [Prognostic importance of beta-2-microglobulin in multiple myeloma]. Rev Invest Clin. 1992; 44(2):215-20.
Field-Smith A, Morgan GJ, Davies FE. Bortezomib (Velcadetrade mark) in the Treatment of Multiple Myeloma. Ther Clin Risk Manag. 2006;2(3):271-9.
Bladé J, Kyle RA. Multiple myeloma in young patients: clinical presentation and treatment approach. Leuk Lymphoma. 1998;30(5-6):493-501.
Kumar B, Yadav P, Nadeem M, Garg MK. An atypical presentation of multiple myeloma in a young patient with pathological fracture. J Family Med Prim Care. 2020;9(6):3154-6.
Sharma A, Preuss CV. Bortezomib. In: StatPearls. Treasure Island (FL): StatPearls Publishing. 2022.
